Bexarotene, an anti-cancer drug which is about to be tested in a clinical trial as a potential treatment for Alzheimer's disease, fails to reduce amyloid plagues; according to researchers replicating the original study.
A new study has pinpointed a catalytic trigger for the onset of Alzheimer's disease. The findings could play a central role in the diagnostics and new drug development for neurodegenerative diseases.
Researchers have identified biomarkers for Alzheimer's disease which accurately predict the development of the disease years prior to symptoms developing.
Researchers used a specific molecule in green tea extract, EGCG, to control metal associated amyloid beta aggregates associated with Alzheimer's disease and other neurodegenerative disorders.
A new study identifies a potential treatment window of several years for plaques in the brain considered to cause memory loss in diseases such as Alzheimer's.
Researchers have discovered that amyloid peptides are harmful to the blood vessels that supply the brain with blood in Alzheimer's disease, thus accelerating cognitive decline by limiting oxygen-rich blood and nutrients.
A protein associated with neuron damage in Alzheimer's patients provides a superior scaffold for growing central nervous system cells in the lab.
Researchers found a key difference in the brains of people with Alzheimer’s disease and those who are cognitively normal but still have brain plaques that characterize this type of dementia.
An international research team revealed the atomic‐level structure of the human peptidase enzyme meprin β (beta).
